Loading...
GRCL logo

Gracell Biotechnologies Inc.NasdaqGS:GRCL Stock Report

Market Cap US$990.8m
Share Price
n/a
1Y388.1%
7D-0.2%
1D0.05%
Portfolio Value
​
View

Gracell Biotechnologies Inc.

NasdaqGS:GRCL Stock Report

Market Cap: US$990.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Gracell Biotechnologies (GRCL) Stock Overview

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. More details

GRCL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months

Earnings are forecast to decline by an average of 5.5% per year for the next 3 years

Makes less than USD$1m in revenue (CN¥0)

Shareholders have been diluted in the past year

+ 1 more risk

GRCL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW502,015 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
502,015 investors already sharing narratives
View all narratives

Gracell Biotechnologies Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gracell Biotechnologies
Historical stock prices
Current Share PriceUS$10.25
52 Week HighUS$10.44
52 Week LowUS$1.40
Beta-0.35
1 Month Change2.30%
3 Month Change93.40%
1 Year Change388.10%
3 Year Change-57.85%
5 Year Changen/a
Change since IPO-59.10%

Recent News & Updates

Seeking Alpha • Feb 21

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a potential milestone payment of $1.5 per ADR. The broad CVR agreement allows multiple ways for AstraZeneca to cash in on the full CVR, increasing the potential value of the acquisition. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Feb 21

AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a potential milestone payment of $1.5 per ADR. The broad CVR agreement allows multiple ways for AstraZeneca to cash in on the full CVR, increasing the potential value of the acquisition. Read the full article on Seeking Alpha
Seeking Alpha • Sep 22

Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform

Citi has initiated Gracell Biotechnologies (NASDAQ:GRCL) with a buy rating highlighting the speed of the company's autologous CAR-T platform manufacturing compared to competitors. The firm has a $12 price target (~422% upside based on Wednesday's close). Analyst Yigal Nochomovitz said that FasTCAR, the CAR-T platform, can manufacture in 22-36 hours compared to the industry average of one to six weeks. He added this will cut the "autologous CAR-T vein-to-vein time from the industry average ~20-35 days to ~11-14 days." The company's lead candidate is GC012F, a dual BCMA/CD19 FasTCAR candidate for multiple myeloma, currently in phase 1. Nochomovitz noted that data on the asset presented earlier this year found it "shaping up to be highly competitive with Legend Biotech's (LEGN) and Johnson & Johnson's (JNJ) Carvykti (ciltacabtagene autoleucel)" in terms of objective response rate and complete response. He added he sees IND filings for GC012F in the US and China by the end of the year. Seeking Alpha's Quant Rating views Gracell (GRCL) as a hold with high marks for revisions and valuation.
Seeking Alpha • Aug 15

Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02

Gracell Biotechnologies press release (NASDAQ:GRCL): Q2 GAAP EPS of -$0.06 beats by $0.02. As of June 30, 2022, the Company had RMB1,707.3 million (US$254.9 million) in cash and cash equivalents and short-term investments. In addition,
Seeking Alpha • Aug 01

Gracell Biotechnologies rallies after naming new chief medical officer

Gracell Biotechnologies (NASDAQ:GRCL) announced Monday the appointment of Wendy Li as its new chief medical officer. Li brings in over 20 years of experience in pharmaceutical industry across the US and China markets with expertise in leading early- and late-stage clinical trials for several therapeutic candidates for the treatment of hematological malignancies. Prior to joining Gracell, Dr. Li served as CMO of EXUMA Biotech, where she provided strategic medical and clinical leadership for the advancement of its cell therapy pipeline in the U.S. and Asia. "Dr. Li's decades of experience in leading clinical development and strategy across many types of cancers and treatment modalities, as well as expertise in working with regulatory agencies, will be invaluable as we continue to advance our pipeline of breakthrough cell therapies and approach the filing of our U.S. IND application for GC012F later this year," said Dr. William (Wei) Cao, Founder, Chairman and CEO of Gracell. Stock is up 23% in premarket trading. Earlier: Gracell names Dr. Samuel Zhang as Chief Business Officer
Seeking Alpha • Jul 19

Gracell names Dr. Samuel Zhang as Chief Business Officer

Gracell Biotechnologies (NASDAQ:GRCL) has announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer. In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including structuring, negotiating and executing of strategic alliances and collaborations.
Seeking Alpha • Nov 26

Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment

Gracell Bio stands to benefit from tax credits and marketing exclusivity following receipt of ‘orphan drug’ status for its CAR-T cancer treatment. The global CAR T-cell therapy market is projected to grow from $1.1 billion in sales in 2020 to $21.8 billion by 2031, representing a compound annual growth rate of 30.6%. Analysts see profitability several years away as competition heats up for treatment of relatively low-occurring cancer.

Shareholder Returns

GRCLUS BiotechsUS Market
7D-0.2%4.0%-0.7%
1Y388.1%42.5%20.3%

Return vs Industry: GRCL exceeded the US Biotechs industry which returned 5.8% over the past year.

Return vs Market: GRCL exceeded the US Market which returned 22.3% over the past year.

Price Volatility

Is GRCL's price volatile compared to industry and market?
GRCL volatility
GRCL Average Weekly Movement19.0%
Biotechs Industry Average Movement10.4%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: GRCL's share price has been volatile over the past 3 months.

Volatility Over Time: GRCL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017314William Caowww.gracellbio.com

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies.

Gracell Biotechnologies Inc. Fundamentals Summary

How do Gracell Biotechnologies's earnings and revenue compare to its market cap?
GRCL fundamental statistics
Market capUS$990.82m
Earnings (TTM)-US$69.13m
Revenue (TTM)n/a
0.0x
P/S Ratio
-14.3x
P/E Ratio

Is GRCL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRCL income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
Other ExpensesCN¥496.98m
Earnings-CN¥496.98m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio6.4%

How did GRCL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/21 13:50
End of Day Share Price 2024/02/21 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gracell Biotechnologies Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Louise ChenCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc